DOI: 10.1002/chem.201304776
Communication
&
Total Synthesis
Stereocontrol by Quaternary Centres: A Stereoselective Synthesis
of (À)-Luminacin D
Nathan Bartlett,[a] Leona Gross,[a] Florent Pꢀron,[a] Daniel J. Asby,[a] Matthew D. Selby,[b]
Ali Tavassoli,[a] and Bruno Linclau*[a]
There is comparatively little information about the mode of
Abstract: Very high diastereoselectivity can be achieved
by 1,3-chelation-controlled allylation of aldehydes that
action or biological function of luminacin D. Given that it is the
most potent member of this family in several of the originally
reported assays,[3] there is significant potential and need for an
possess a non-chelating a-ether substituent, even if the
a-position is a quaternary centre and/or a spiro-epoxide.
approach that enables the synthesis of sufficient quantities of
This reaction was used as a key step in an enantioselective
this molecule to enable further research into its cellular mode
synthesis of the angiogenesis inhibitor luminacin D.
of action.
There are a few syntheses of the luminacins reported,[7] how-
ever, each with shortcomings in terms of length and/or unse-
Natural products continue to be a robust source of novel ther-
apeutics, with approximately 50% of currently approved anti-
cancer drugs being natural products or their derivatives.[1] The
luminacin family of natural products, discovered from the fer-
mentation broth of the soil bacterium Streptomyces sp.,[2] con-
tains several members that have shown promising anticancer
activity in multiple assays and cell lines. Two members of this
family, luminacin D (1a) and luminacin C2 (1b, also known as
UCS15A), have been shown to be potent inhibitors of angio-
genesis in several in vitro assays.[3] Luminacin D was also
shown to inhibit the proliferation of several cancer cell lines.[3]
Additional studies with luminacin C2 have shown it to be
a protein–protein interaction inhibitor that targets Src signal
transduction by inhibiting the SH3 domain-mediated interac-
tions of Src kinase with its targets, thus preventing the Src-spe-
cific tyrosine phosphorylation of numerous proteins.[4] Src kin-
ases play a key role in the signalling and regulation of multiple
processes associated with cancer, such as cell migration, cell
adhesion, extracellular matrix sensing, cell cycle timing, as well
as several poorly understood events necessary for angiogene-
sis.
lective reaction steps. A particular concern is the epoxide intro-
duction, with three total syntheses featuring a late stage-epox-
idation step with very low, or undesired selectivity.[7b–d,8] Be-
cause of this, we sought to develop a synthetic approach in
which an enantiopure epoxide intermediate is assembled first,
to then utilise its stereochemistry for diastereoselective com-
pletion of the aliphatic portion, from which the luminacins and
the migracins can be synthesised.
Herein we report a successful total synthesis of (À)-lumina-
cin D using this strategy, and report on the excellent diastereo-
control possible by allylation of aldehydes having a-oxygenat-
ed centres, including quaternary centres, under 1,3-chelation
conditions. We also unambiguously show that this type of al-
dehyde addition is consistent with the Cornforth–Evans (CE)
model of stereoinduction.
Hence, conventional disconnection leads to the aliphatic
fragment 2 (Scheme 1). Its construction was envisaged by
spontaneous hemiacetal ring closure, syn-aldol reaction, and
by the key step, diastereoselective allylation controlled by 1,2-
induction of the quaternary epoxide centre of the enantiopure
intermediate 3. This chelation-controlled allylation step was in-
spired by previous work from our group showing excellent
levels of diastereocontrol exerted by all-C quaternary stereo-
centres for allylstannation of 2,2-disubstituted malonalde-
hydes.[9] However, a 1,3-dialdehyde group (c.f. 3b) is not desir-
able in the present case, as it contains four diastereotopic alde-
hyde faces, and our efforts were directed to investigating 3a
and 3c as substrates for the allylation reaction.[10] The synthesis
of the enantiopure epoxides 3a,c was envisioned from sub-
strates 4 and 5.
Luminacin C2 was further demonstrated to inhibit the inva-
sion and metastasis of model breast cancer cell lines in vitro,
by inhibition of the protein–protein interaction of the Src-ho-
mology domain of cortactin with AMAP1.[5] The recent report
that two structurally related compounds, named migracin A
and B (1c), inhibit the migration of a breast cancer cell line,[6]
provides further evidence for the anticancer potential of this
molecule, or its derivatives.
Starting from 6, synthesised in three steps from methyl
acrylate,[7c,11] benzylation and reduction gave 4 as a substrate
for a Sharpless epoxidation, which was followed by alcohol oxi-
dation to give 3a (Scheme 2). The 3-oxopropionate substrate
3c was synthesised from enantiopure 7, which was obtained
in one step from the corresponding menthyl sulfinyl ester.
Two-step Knoevenagel condensation led to 5 as the E isomer
[a] N. Bartlett, L. Gross, F. Pꢀron, Dr. D. J. Asby, Dr. A. Tavassoli, Dr. B. Linclau
Department of Chemistry, University of Southampton
Highfield, Southampton SO17 1BJ (UK)
[b] M. D. Selby
UCB, 216 Bath Road, Slough, Berkshire, SL1 WE (UK)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/chem.201304776.
Chem. Eur. J. 2014, 20, 3306 – 3310
3306
ꢁ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim